Pulmonary affectation of vasculitis.
Respiratory tract affectation is frequent in some types of vasculitis, fundamentally in those associated with anti-neutrophil cytoplasmic antibodies (ANCA). The clinical, radiological and histopathological presentation is also heterogeneous and conditions the evolution. It is therefore necessary to establish an early diagnosis based on the symptoms because, thanks to new treatments, and despite them being potentially serious diseases, their prognosis has improved considerably in recent years. The present paper updates the diagnosis and the new therapeutic options for pulmonary vasculitis.
Servicio de Medicina Interna, Hospital Universitario La Paz, Madrid, Spain.
Natalia
N
Martín-Suñé
Juan José
JJ
Ríos-Blanco
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000150:complications / Q000473:pathology / Q000628:therapy; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D003131:Combined Modality Therapy; D015769:Granuloma, Respiratory Tract / Q000209:etiology / Q000473:pathology; D014890:Granulomatosis with Polyangiitis / Q000150:complications / Q000473:pathology / Q000628:therapy; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008168:Lung / Q000098:blood supply; D008171:Lung Diseases / Q000209:etiology* / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D010956:Plasmapheresis; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014657:Vasculitis / Q000145:classification / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000628:therapy
D000305:Adrenal Cortex Hormones; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D008727:Methotrexate